title: [Nitric oxide, from vascular physiology to therapeutics].
abstract: Nitric oxide (NO) synthesised by endothelial cells, plays a key role in the control of vascular tone. Its synthesis from L-arginine is assured by NO-synthase, the activity of which is dependent on intracellular calcium concentrations, which are themselves modulated by pharmacological (acetylcholine, serotonin, bradykinin...) or physical factors (shearing forces exerted by blood flow). NO acts by stimulating a soluble guanylate-cyclase of the smooth muscle cells in the vessel wall. Its vasodilator effect is therefore mediated by an increase in intracellular cyclic GMP concentration. The synthesis or liberation of NO by the endothelium may be decreased or abolished during many pathological processes (hypercholesterolaemia, atherosclerosis, systemic or pulmonary hypertension...). The significance of this abnormality of NO-mediated endothelium-dependent vasodilation in different pathological conditions has not been established. However, it is probably significant in view of the different properties of NO: vaso-relaxation, antiaggregant and inhibition of vascular smooth muscle growth. It is not yet known whether this abnormality is a cause or a consequence of the underlying disease. From the therapeutic point of view, NO is an active metabolite of nitrate derivatives, sodium nitroprussiate and molsidomine which therefore share the same mode of action as the so-called "endothelium-dependent" vasodilatoe agents. The inhalation of NO, which is increasingly used in neonatal and adult intensive care units, is an alternative therapeutic approach in many conditions associated with pulmonary hypertension.
authors.affiliation: Département de physiologie, hôpital Henri-Mondor, Créteil.
authors.forename: S
authors.initials: S
authors.lastname: Adnot
authors.forename: S
authors.initials: S
authors.lastname: Eddahibi
authors.forename: P
authors.initials: P
authors.lastname: Mauran
authors.forename: P
authors.initials: P
authors.lastname: Andrivet
authors.forename: C
authors.initials: C
authors.lastname: Carville
authors.forename: B
authors.initials: B
authors.lastname: Raffestin
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D004730:Endothelium, Vascular / Q000502:physiology; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage / Q000502:physiology* / Q000627:therapeutic use; D014664:Vasodilation / Q000502:physiology
chemical_list: D009569:Nitric Oxide
vernacular_title: Le monoxyde d'azote, de la physiologie vasculaire à la thérapeutique.